![Dirk Brockstedt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dirk Brockstedt
Berater bei
ShangPharma Innovation, Inc.
Profil
Dirk G.
Brockstedt is currently Executive-in-Residence at ShangPharma Innovation, Inc. Former positions include Chief Scientific Officer at Rapt Therapeutics, Inc. from 2018 to 2026, Executive Vice President-Research & Development at Aduro BioTech, Inc. from 2016 to 2017, Director-Research at Anza Therapeutics, Inc. from 2007 to 2009, Immunology Director at Cerus Corp.
from 2002 to 2007, and Senior Research Scientist at Aventis, Inc. Education includes graduate and doctorate degrees from the University of Kiel.
Aktive Positionen von Dirk Brockstedt
| Unternehmen | Position | Beginn |
|---|---|---|
ShangPharma Innovation, Inc.
 ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation invests in companies located in the United States. The firm targets companies operating in the fields of healthcare sector. It provides financing for seed to early stage capital requirements. | Berater | - |
Ehemalige bekannte Positionen von Dirk Brockstedt
| Unternehmen | Position | Ende |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 03.03.2026 |
| CHINOOK THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2017 |
Anza Therapeutics, Inc.
 Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic vaccines for cancer and infectious diseases | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2009 |
| CERUS CORPORATION | Corporate Officer/Principal | 01.01.2007 |
Aventis, Inc.
 Aventis, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Corporate Officer/Principal | - |
Ausbildung von Dirk Brockstedt
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
59
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Cerus Corp.
 Cerus Corp. Medical SpecialtiesHealth Technology Develops and commercializes the INTERCEPT Blood System for platelets and plasma | Health Technology |
Aventis, Inc.
Aventis, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company, which focuses on the development of technology platforms for cancer | Health Technology |
University of Kiel
 University of Kiel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anza Therapeutics, Inc.
Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic vaccines for cancer and infectious diseases | Health Technology |
Rapt Therapeutics, Inc.
 Rapt Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes oral small molecule therapies for patients | Health Technology |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation invests in companies located in the United States. The firm targets companies operating in the fields of healthcare sector. It provides financing for seed to early stage capital requirements. | Finance |
